<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Velaglucerase alfa (glucocerebrosidase): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Velaglucerase alfa (glucocerebrosidase): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Velaglucerase alfa (glucocerebrosidase): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9979" href="/d/html/9979.html" rel="external">see "Velaglucerase alfa (glucocerebrosidase): Drug information"</a> and <a class="drug drug_patient" data-topicid="12332" href="/d/html/12332.html" rel="external">see "Velaglucerase alfa (glucocerebrosidase): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9942752"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vpriv</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871151"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Vpriv</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10206018"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Enzyme, Glucocerebrosidase</span>;</li>
<li>
<span class="list-set-name">Gaucher's Disease, Treatment Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F9961703"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pretreatment with antihistamines and/or corticosteroids can be considered for prevention of subsequent infusion reactions in patients with hypersensitivity reactions requiring symptomatic treatment; during clinical studies, patients were not routinely premedicated prior to infusion.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f2b4b875-de3a-4095-90bd-c85570a212a5">Gaucher disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gaucher disease (type 1):</b> Children ≥4 years and Adolescents: IV: 60 units/kg every other week; adjust based upon disease activity; dosing range: 15 to 60 units/kg every other week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24612151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24612151'])">Ref</a></span>). <b>Note:</b> When switching from imiglucerase to velaglucerase alfa, initiate velaglucerase alfa treatment 2 weeks after the last imiglucerase dose and at the same dose as stable imiglucerase therapy.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51193259"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51193260"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F9961744"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9979" href="/d/html/9979.html" rel="external">see "Velaglucerase alfa (glucocerebrosidase): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pretreatment with antihistamines and/or corticosteroids can be considered for prevention of subsequent infusion reactions in patients with hypersensitivity reactions requiring symptomatic treatment; during clinical studies, patients were not routinely premedicated prior to infusion.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f2b4b875-de3a-4095-90bd-c85570a212a5">Gaucher disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gaucher disease (type 1):</b>
<b>IV:</b> 60 units/kg administered every 2 weeks; adjust dose based upon disease activity (range: 15 to 60 units/kg evaluated in clinical trials).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When switching from imiglucerase to velaglucerase alfa in stable patients, initiate treatment 2 weeks after the last imiglucerase dose and at the same dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990017"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987292"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F9961686"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (15% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Prolonged partial thromboplastin time (5% to 11%; more common in children and adolescents)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (23% to 52%; including anaphylaxis: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (8% to 22%), fatigue (≤15%), headache (30% to 35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (8% to 15%; knee), asthenia (≤15%), back pain (17% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (13% to 22%; more common in children and adolescents)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (&gt;2%), hypertension (&gt;2%), hypotension (&gt;2%), tachycardia (&gt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (&gt;2%; more common in children and adolescents), urticaria (&gt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (6% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (neutralizing: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Ostealgia (&gt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Gastrointestinal: Vomiting</p></div>
<div class="block coi drugH1Div" id="F9961603"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Hypersensitivity to velaglucerase alfa or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F9961684"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: The development of IgG antibodies has been reported; the clinical significance is unknown. Patients with an immune response to other enzyme replacement therapies who are switching to velaglucerase alfa should be monitored for antibody development.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Use with caution in patients who have exhibited hypersensitivity reactions to velaglucerase alfa or other enzyme replacement therapies. Anaphylaxis has occurred; appropriate medical support should be readily available in the event of a serious reaction. The most common hypersensitivity reactions reported in clinical trials include asthenia, dizziness, fatigue, fever, headache, hyper-/hypotension, nausea, and pyrexia. Most reactions were mild and occurred during the first 6 months of treatment. Management strategies of more severe reactions include symptomatic treatment, pretreatment with antihistamines, antipyretics, and/or corticosteroids, and slowing of the infusion rate. Treatment should be discontinued if anaphylaxis or other acute reactions occur.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878772"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Pediatric patients (4 to 17 years) may experience a higher frequency of some adverse effects than adults (&gt;10% difference in incidence), including fever, rash, and prolonged aPTT.</p></div>
<div class="block foc drugH1Div" id="F9961750"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vpriv: 400 units (1 ea)</p></div>
<div class="block geq drugH1Div" id="F9961594"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322831"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Vpriv Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 unit (per each): $1,753.03</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871152"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vpriv: 400 units (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52614451"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: For IV administration. Infuse over 60 minutes through an in-line low protein-binding 0.2 or 0.22 micron filter. Do not infuse other products in the same infusion tubing.</p></div>
<div class="block adm drugH1Div" id="F9961746"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Infuse over 1 hour; use an inline, low protein-binding 0.2- or 0.22-micron filter during infusion. Do not infuse other products in the same infusion tubing.</p></div>
<div class="block sts drugH1Div" id="F9961691"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 8°C (36°F to 46°F). Once reconstituted, the product should be used immediately. If immediate use is not possible, the reconstituted or diluted product may be stored for up to 24 hours at 2°C to 8°C (36°F to 46°F). The infusion should be completed within 24 hours of reconstitution. Do not freeze. Protect from light. Discard any unused solution.</p></div>
<div class="block usep drugH1Div" id="F53570855"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Long-term enzyme replacement therapy for patients with Type 1 Gaucher disease (FDA approved in ages ≥4 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F13300212"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F10073433"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F9961601"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on available information, an increased risk of adverse pregnancy outcomes has not been observed following maternal use of velaglucerase alfa (Elstein 2014; Lau 2018). Pregnancy may exacerbate existing type I Gaucher disease or result in new symptoms. Women with type I Gaucher disease have an increased risk of spontaneous abortion if disease is not well controlled. Adverse pregnancy outcomes, including hepatosplenomegaly and thrombocytopenia, may occur.</p></div>
<div class="block mopp drugH1Div" id="F53570854"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, liver enzymes, IgG antibodies; MRI, CT, or US of liver and spleen; bone density studies; monitor antibodies in those patients who developed antibodies to other enzyme replacement therapies</p></div>
<div class="block pha drugH1Div" id="F9961693"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Velaglucerase alfa, which contains the same amino acid sequence as  endogenous glucocerebrosidase, catalyzes the hydrolysis of glucocerebroside to glucose and ceramide in the lysosome. In patients with type 1 Gaucher’s disease, glucocerebrosidase deficiency results in accumulation of glucocerebroside in macrophages, thereby causing the associated signs and symptoms. Velaglucerase alfa is used to diminish hepatosplenomegaly and improve anemia, thrombocytopenia, and bone disease.</p></div>
<div class="block phk drugH1Div" id="F9961695"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;">
<b>Note:</b> Values reported below based on combined pediatric patient (4-17 years) and adult data.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Steady-state: 0.08-.0.11 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 11-12 minutes</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10962020"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Vpriv</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-14677062">
<a name="14677062"></a>Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. <i>Eur J Pediatr. </i>2004;163(2):67-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velaglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/14677062/pubmed" id="14677062" target="_blank">14677062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14722528">
<a name="14722528"></a>Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. <i>J Pediatr. </i>2004;144(1):112-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velaglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/14722528/pubmed" id="14722528" target="_blank">14722528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24612151">
<a name="24612151"></a>Elstein D, Hughes D, Goker-Alpan O, et al. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease [published correction appears in <i>J Obstet Gynaecol Res</i>. 2014;40(9):2088]. <i>J Obstet Gynaecol Res</i>. 2014;40(4):968-975. doi: 10.1111/jog.12254.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velaglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/24612151/pubmed" id="24612151" target="_blank">24612151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28851512">
<a name="28851512"></a>Elstein D, Mellgard B, Dinh Q, et al. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials. <i>Mol Genet Metab</i>. 2017;122(1-2):113-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velaglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/28851512/pubmed" id="28851512" target="_blank">28851512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15813845">
<a name="15813845"></a>Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. <i>Br J Haematol. </i>2005;129(2):178-188.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velaglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/15813845/pubmed" id="15813845" target="_blank">15813845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27839985">
<a name="27839985"></a>Lau H, Belmatoug N, Deegan P, et al. Reported outcomes of 453 pregnancies in patients with Gaucher disease: an analysis from the Gaucher outcome survey. <i>Blood Cells Mol Dis</i>. 2018;68:226-231. doi: 10.1016/j.bcmd.2016.10.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velaglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/27839985/pubmed" id="27839985" target="_blank">27839985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15468045">
<a name="15468045"></a>Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. <i>Semin Hematol. </i>2004;41(4 Suppl 5):4-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velaglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/15468045/pubmed" id="15468045" target="_blank">15468045</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vpriv (velaglucerase alfa) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; September 2021.</div>
</li>
<li>
<div class="reference">
                  Vpriv (velaglucerase alfa) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; received December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15468046">
<a name="15468046"></a>Weinreb NJ, Aggio MC, Andersson HC, et al; International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. <i>Semin Hematol. </i>2004;41(4 Suppl 5):15-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/velaglucerase-alfa-glucocerebrosidase-pediatric-drug-information/abstract-text/15468046/pubmed" id="15468046" target="_blank">15468046</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15623 Version 121.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
